Treg infiltration in glioma: A hurdle for antiglioma immunotherapy

Immunotherapy

Volumn 4, Issue 7, 2012, Pages 675-678

  Vandenberk, Lien ^a   Van Gool, Stefaan W ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Pediatric Neuro oncology   (Belgium)

Author keywords

glioma; immunotherapy; Treg; tumor microenvironment

Indexed keywords

CANCER IMMUNOTHERAPY; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE DEFICIENCY; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; NOTE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

EID: 84864598740     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.64     Document Type: Note

References (22)

1. Crane CA, Ahn BJ, Han SJ, Parsa AT. Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy. Neuro Oncol. 14(5), 584-595 (2012).
2. Finocchiaro G, Pellegatta S. Immunotherapy for glioma: getting closer to the clinical arena? Curr. Op in Neurol. 24(6), 641-647 (2011).
3. Humphries W, Wei J, Sampson JH, Heimberger AB. The role of tregs in glioma-mediated immunosuppression: potential target for intervention. Neurosurg. Clin. N. Am. 21(1), 125-137 (2010).
4. + regulatory T cells in human gliomas. Clin. Cancer Res. 14(16), 5166-5172 (2008).
5. Jacobs JF, Idema AJ, Bol KF et al. Prognostic signifcance and mechanism of Treg infltration in human brain tumors. J. Neuroimmunol. 225(1-2), 195-199 (2010).
6. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int. J. Cancer 127(4), 759-767 (2010).
7. Jordan JT, Sun W, Hussain SF, Deangulo G, Prabhu SS, Heimberger AB. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol. Immunother. 57(1), 123-131 (2008).
8. Avril T, Vauleon E, Tanguy-Royer S, Mosser J, Quillien V. Mechanisms of immunomodulation in human glioblastoma. Immunotherapy 3 (Suppl. 4), 42-44 (2011).
9. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3(11), 991-998 (2002).
10. Maes W, Rosas GG, Verbinnen B et al. DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma experimental glioma. Neuro Oncol. 11(5), 529-542 (2009).
11. + T cells in mice. Immunol. Cell Biol. 89(1), 130-142 (2011).
12. Heimberger AB, Sun W, Hussain SF et al. Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol. 10(1), 98-103 (2008).
13. Ghiringhelli F, Menard C, Puig PE et al. Metronomic cyclophosphamide regimen selectively depletes CD4 + CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56(5), 641-648 (2007).
14. Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E, Zitvogel L. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin. Immunopathol. 33(4), 369-383 (2011).
15. Vermeij R, Leffers N, Hoogeboom BN et al. Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm Phase II study. Int. J. Cancer doi:10.1002/ijc.27388 (2011) (Epub ahead of print).
16. Huijts CM, Santegoets SJ, van den Eertwegh AJ et al. Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer. BMC Cancer 11(1), 505 (2011).
17. Ge Y, Domschke C, Stoiber N et al. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol. Immunother. 61(3), 353-362 (2011).
18. Viaud S, Flament C, Zoubir M et al. Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res. 71(3), 661-665 (2011).
19. North RJ. Gamma-irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells. Cancer Immunol. Immunother. 16(3), 175-181 (1984).
20. Ardon H, Van Gool S, Verschuere T et al. Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 Phase I/II trial. Cancer Immunol. Immunother. doi:10.1007/s00262-012-1261-1 (2012) (Epub ahead of print).
21. Van Gool S, Maes W, Ardon H, Verschuere T, Van Cauter S, De Vleeschouwer S. Dendritic cell therapy of high-grade gliomas. Brain Pathol. 19(4), 694-712 (2009).
22. De Vleeschouwer S, Ardon H, Van Calenbergh F et al. Stratifcation according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by postoperative dendritic cell vaccination. Cancer Immunol. Immunother. doi:10.1007/s00262-012-1271-z (2012) (Epub ahead of print).